Last reviewed · How we verify
Risperidone ISM
At a glance
| Generic name | Risperidone ISM |
|---|---|
| Also known as | OKEDI®, No other names |
| Sponsor | Rovi Pharmaceuticals Laboratories |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
- Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (PHASE1)
- Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension (PHASE3)
- Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia (PHASE3)
- Comparative Bioavailability of Risperidone. (PHASE1)
- Comparative Bioavailability of Risperidone (PHASE1)
- Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia (PHASE2)
- Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone ISM CI brief — competitive landscape report
- Risperidone ISM updates RSS · CI watch RSS
- Rovi Pharmaceuticals Laboratories portfolio CI